EP3691692B8 - Anti-cd71 activatable antibody drug conjugates and methods of use thereof - Google Patents

Anti-cd71 activatable antibody drug conjugates and methods of use thereof Download PDF

Info

Publication number
EP3691692B8
EP3691692B8 EP18797311.0A EP18797311A EP3691692B8 EP 3691692 B8 EP3691692 B8 EP 3691692B8 EP 18797311 A EP18797311 A EP 18797311A EP 3691692 B8 EP3691692 B8 EP 3691692B8
Authority
EP
European Patent Office
Prior art keywords
methods
drug conjugates
antibody drug
activatable antibody
activatable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18797311.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3691692B1 (en
EP3691692A1 (en
Inventor
Shweta SINGH
Jennifer Hope RICHARDSON
Laura Patterson SERWER
Jonathan Alexander Terrett
Susan E. Morgan-Lappe
Tracy HENRIQUES
Sherry L. RALSTON
Marvin Robert Leanna
Ilaria BADAGNANI
Sahana Bose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Priority to HRP20210436TT priority Critical patent/HRP20210436T8/hr
Priority to EP20209320.9A priority patent/EP3834846A1/en
Priority to SI201830233T priority patent/SI3691692T1/sl
Priority to RS20210341A priority patent/RS61596B1/sr
Priority to PL18797311T priority patent/PL3691692T3/pl
Publication of EP3691692A1 publication Critical patent/EP3691692A1/en
Application granted granted Critical
Publication of EP3691692B1 publication Critical patent/EP3691692B1/en
Publication of EP3691692B8 publication Critical patent/EP3691692B8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18797311.0A 2017-10-14 2018-10-12 Anti-cd71 activatable antibody drug conjugates and methods of use thereof Active EP3691692B8 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
HRP20210436TT HRP20210436T8 (hr) 2017-10-14 2018-10-12 Konjugati protutijela s lijekom koje može aktivirati protutijelo protiv cd71 i postupci njihove upotrebe
EP20209320.9A EP3834846A1 (en) 2017-10-14 2018-10-12 Anti-cd71 activatable antibody drug conjugates and methods of use thereof
SI201830233T SI3691692T1 (sl) 2017-10-14 2018-10-12 Konjugati anti-CD71 aktivacije sposobnega protitelesa in zdravila ter postopki uporabe le-teh
RS20210341A RS61596B1 (sr) 2017-10-14 2018-10-12 Anti-cd71 aktivirani konjugati leka-antitela i metode njihovog korišćenja
PL18797311T PL3691692T3 (pl) 2017-10-14 2018-10-12 Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14
PCT/US2018/055733 WO2019075417A1 (en) 2017-10-14 2018-10-12 CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP20209320.9A Division EP3834846A1 (en) 2017-10-14 2018-10-12 Anti-cd71 activatable antibody drug conjugates and methods of use thereof
EP20209320.9A Division-Into EP3834846A1 (en) 2017-10-14 2018-10-12 Anti-cd71 activatable antibody drug conjugates and methods of use thereof

Publications (3)

Publication Number Publication Date
EP3691692A1 EP3691692A1 (en) 2020-08-12
EP3691692B1 EP3691692B1 (en) 2020-12-30
EP3691692B8 true EP3691692B8 (en) 2021-05-26

Family

ID=64110112

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18797311.0A Active EP3691692B8 (en) 2017-10-14 2018-10-12 Anti-cd71 activatable antibody drug conjugates and methods of use thereof
EP20209320.9A Pending EP3834846A1 (en) 2017-10-14 2018-10-12 Anti-cd71 activatable antibody drug conjugates and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20209320.9A Pending EP3834846A1 (en) 2017-10-14 2018-10-12 Anti-cd71 activatable antibody drug conjugates and methods of use thereof

Country Status (34)

Country Link
US (3) US20190111150A1 (ko)
EP (2) EP3691692B8 (ko)
JP (2) JP7374891B2 (ko)
KR (4) KR20220045088A (ko)
CN (1) CN111278467A (ko)
AR (1) AR115178A1 (ko)
AU (1) AU2018346969A1 (ko)
BR (1) BR112020007302B1 (ko)
CA (1) CA3077730A1 (ko)
CL (1) CL2020000977A1 (ko)
CO (1) CO2020005685A2 (ko)
CR (1) CR20200206A (ko)
CY (1) CY1123968T1 (ko)
DK (1) DK3691692T3 (ko)
DO (1) DOP2023000150A (ko)
EC (1) ECSP20025198A (ko)
ES (1) ES2864013T3 (ko)
HR (1) HRP20210436T8 (ko)
HU (1) HUE054037T2 (ko)
IL (1) IL273586A (ko)
LT (1) LT3691692T (ko)
MA (1) MA50752B1 (ko)
MD (1) MD3691692T2 (ko)
MX (1) MX2020003723A (ko)
PE (1) PE20210125A1 (ko)
PL (1) PL3691692T3 (ko)
PT (1) PT3691692T (ko)
RS (1) RS61596B1 (ko)
RU (2) RU2771292C2 (ko)
SG (1) SG11202003378WA (ko)
SI (1) SI3691692T1 (ko)
TW (2) TWI780237B (ko)
UY (1) UY37931A (ko)
WO (1) WO2019075417A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
BR112017023862A2 (pt) * 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
CA3179911A1 (en) * 2020-04-08 2021-10-14 Janssen Biotech, Inc. Compositions and methods for blood-brain barrier delivery
WO2021207657A1 (en) * 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
WO2024026474A1 (en) * 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001513A1 (en) 1986-08-28 1988-03-10 Teijin Limited Cytocidal antibody complex and process for its preparation
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP1919931A4 (en) 2005-08-31 2010-01-20 Univ California CELLULAR LIBRARIES OF PEPTIDE SEQUENCES (CLIPS) AND METHODS OF USE THEREOF
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
EP2570137A3 (en) * 2007-11-07 2013-08-21 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP2385955B1 (en) 2009-01-12 2020-08-12 CytomX Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
ES2725356T3 (es) * 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos monoclonales de ERG2 y su uso terapéutico
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
SG191977A1 (en) * 2011-02-01 2013-08-30 Genmab As Human antibodies and antibody-drug conjugates against cd74
HUE054362T2 (hu) * 2012-01-31 2021-09-28 Sbi Biotech Co Ltd Foszfolipáz D4 elleni antitest
WO2014026136A2 (en) 2012-08-10 2014-02-13 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
KR102535900B1 (ko) * 2013-12-25 2023-05-26 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
BR112017023862A2 (pt) * 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用

Also Published As

Publication number Publication date
TWI780237B (zh) 2022-10-11
PL3691692T3 (pl) 2021-07-19
KR20230004932A (ko) 2023-01-06
EP3834846A1 (en) 2021-06-16
HRP20210436T1 (hr) 2021-04-30
KR102529359B1 (ko) 2023-05-09
ECSP20025198A (es) 2020-06-30
PT3691692T (pt) 2021-03-29
TW201927815A (zh) 2019-07-16
KR20220045088A (ko) 2022-04-12
JP2020537649A (ja) 2020-12-24
WO2019075417A1 (en) 2019-04-18
AU2018346969A1 (en) 2020-04-23
MA50752B1 (fr) 2021-03-31
DK3691692T3 (da) 2021-03-22
RU2020115713A (ru) 2021-11-16
SI3691692T1 (sl) 2021-04-30
KR20230070046A (ko) 2023-05-19
BR112020007302B1 (pt) 2023-01-31
MA50752A (fr) 2020-08-12
PE20210125A1 (es) 2021-01-19
BR112020007302A2 (pt) 2020-09-29
US20190111150A1 (en) 2019-04-18
MX2020003723A (es) 2020-07-22
RS61596B1 (sr) 2021-04-29
KR20200070324A (ko) 2020-06-17
RU2771292C2 (ru) 2022-04-29
AR115178A1 (es) 2020-12-09
CO2020005685A2 (es) 2020-05-15
HRP20210436T8 (hr) 2022-01-07
IL273586A (en) 2020-05-31
US20210145978A1 (en) 2021-05-20
CR20200206A (es) 2021-02-18
UY37931A (es) 2019-04-30
CN111278467A (zh) 2020-06-12
LT3691692T (lt) 2021-05-10
ES2864013T3 (es) 2021-10-13
RU2020115713A3 (ko) 2022-02-25
US20240115724A1 (en) 2024-04-11
EP3691692B1 (en) 2020-12-30
KR102385495B1 (ko) 2022-04-15
SG11202003378WA (en) 2020-05-28
MD3691692T2 (ro) 2021-05-31
CA3077730A1 (en) 2019-04-18
JP2024012366A (ja) 2024-01-30
RU2022111211A (ru) 2022-05-05
CL2020000977A1 (es) 2020-09-11
DOP2023000150A (es) 2023-08-31
TW202330039A (zh) 2023-08-01
JP7374891B2 (ja) 2023-11-07
HUE054037T2 (hu) 2021-08-30
EP3691692A1 (en) 2020-08-12
CY1123968T1 (el) 2022-05-27

Similar Documents

Publication Publication Date Title
EP3706803A4 (en) CONJUGATES OF BIOMOLECULES AND THEIR USES
EP3337517A4 (en) ANTI-DLL3 ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE
IL270921A (en) Activatable anti-PDL1 antibodies and methods of using them
EP3634485A4 (en) CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
EP3386536A4 (en) COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF
EP3691692B8 (en) Anti-cd71 activatable antibody drug conjugates and methods of use thereof
EP3580239A4 (en) ANTIBODY ANTI-ILT3 AND ANTIBODY-DRUG CONJUGATES
IL272703A (en) Activatable anti-CD166 antibodies and methods of using them
EP3625253A4 (en) ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
EP3294810A4 (en) Silicon based drug conjugates and methods of using same
EP3595699A4 (en) CARTILLE HOMING PEPTIDE CONJUGATES AND METHOD OF USING THEREOF
EP3638697A4 (en) ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
EP3638290A4 (en) KIDNEY HOMING PEPTIDE CONJUGATES AND METHOD OF USING THEREOF
EP3612567A4 (en) ANTI-VTCN1 ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
EP3746461A4 (en) ACTIVABLE ANTIBODIES AND THEIR MANUFACTURING AND USE PROCESSES
EP3594241A4 (en) IL-13RA2 TARGETING ANTIBODY AND ITS APPLICATION
EP3579860A4 (en) ANTI-TRAILSHORT ANTIBODIES AND METHODS OF USE
EP3448885A4 (en) ANTIBODY CONJUGATES AND METHODS OF MAKING AND USING SAME
EP3703745A4 (en) IMMUNOGENIC CONJUGATES AND METHOD OF USING THEREOF
EP3675907A4 (en) ANTI-EGFR-DRUG (ADC) ANTIBODY CONJUGATES AND ASSOCIATED USES
EP3681541A4 (en) MELANINE ANTIBODIES AND USES THEREOF
EP3601360A4 (en) ANTI-TMEFF1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
IL278225A (en) Anti SEZ6 antibody drug conjugates and methods of use
EP3647325A4 (en) PHARMACEUTICAL COMPOSITION OF PCSK-9 ANTIBODIES AND USES THEREOF
EP3675908A4 (en) ANTI-EGFR-DRUG (ADC) ANTIBODY CONJUGATES AND ASSOCIATED USES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17P Request for examination filed

Effective date: 20200507

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17Q First examination report despatched

Effective date: 20200731

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20201015

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40025681

Country of ref document: HK

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1349280

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018011414

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: RENTSCH PARTNER AG, CH

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20210436

Country of ref document: HR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210317

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3691692

Country of ref document: PT

Date of ref document: 20210329

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20210322

REG Reference to a national code

Ref country code: MA

Ref legal event code: VAGR

Ref document number: 50752

Country of ref document: MA

Kind code of ref document: B1

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

GRAT Correction requested after decision to grant or after decision to maintain patent in amended form

Free format text: ORIGINAL CODE: EPIDOSNCDEC

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 36712

Country of ref document: SK

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG B8

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20210436

Country of ref document: HR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E020550

Country of ref document: EE

Effective date: 20210324

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20210400838

Country of ref document: GR

Effective date: 20210519

RAP4 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: ABBVIE INC.

REG Reference to a national code

Ref country code: MD

Ref legal event code: VAGR

Ref document number: 3691692

Country of ref document: MD

Date of ref document: 20210531

Kind code of ref document: T2

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20201230

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG INHABER

REG Reference to a national code

Ref country code: SK

Ref legal event code: TB4A

Ref document number: E 36712

Country of ref document: SK

Free format text: CORRECTION TO GAZETTE 8/2021 - SC4A, PAGE 20:(73) ABBVIE INC., NORTH CHICAGO, IL, US

REG Reference to a national code

Ref country code: EE

Ref legal event code: HC1A

Ref document number: E020550

Country of ref document: EE

REG Reference to a national code

Ref country code: HU

Ref legal event code: HC9C

Owner name: ABBVIE INC., US

Free format text: FORMER OWNER(S): ABBVIE INC., US

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E054037

Country of ref document: HU

REG Reference to a national code

Ref country code: NL

Ref legal event code: HC

Owner name: ABBVIE INC.; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME; FORMER OWNER NAME: ABBVIE INC.

Effective date: 20210805

REG Reference to a national code

Ref country code: BE

Ref legal event code: HC

Owner name: ABBVIE INC.; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME

Effective date: 20210805

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018011414

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2864013

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211013

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210436

Country of ref document: HR

Payment date: 20211001

Year of fee payment: 4

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20211001

REG Reference to a national code

Ref country code: HR

Ref legal event code: T8IS

Ref document number: P20210436

Country of ref document: HR

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20211001

Year of fee payment: 4

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: TN

Payment date: 20211031

Year of fee payment: 4

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210436

Country of ref document: HR

Payment date: 20221005

Year of fee payment: 5

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20220919

Year of fee payment: 5

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1349280

Country of ref document: AT

Kind code of ref document: T

Effective date: 20201230

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20220915

Year of fee payment: 5

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20221010

Year of fee payment: 5

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210436

Country of ref document: HR

Payment date: 20230919

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20230919

Year of fee payment: 6

Ref country code: NO

Payment date: 20230925

Year of fee payment: 6

Ref country code: NL

Payment date: 20230919

Year of fee payment: 6

Ref country code: MC

Payment date: 20230926

Year of fee payment: 6

Ref country code: LU

Payment date: 20230919

Year of fee payment: 6

Ref country code: IE

Payment date: 20230925

Year of fee payment: 6

Ref country code: GB

Payment date: 20230914

Year of fee payment: 6

Ref country code: FI

Payment date: 20230927

Year of fee payment: 6

Ref country code: EE

Payment date: 20230919

Year of fee payment: 6

Ref country code: CZ

Payment date: 20230921

Year of fee payment: 6

Ref country code: BG

Payment date: 20230920

Year of fee payment: 6

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20230921

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20230915

Year of fee payment: 6

Ref country code: RS

Payment date: 20230927

Year of fee payment: 6

Ref country code: PT

Payment date: 20230925

Year of fee payment: 6

Ref country code: PL

Payment date: 20230915

Year of fee payment: 6

Ref country code: IS

Payment date: 20230925

Year of fee payment: 6

Ref country code: HR

Payment date: 20230919

Year of fee payment: 6

Ref country code: GR

Payment date: 20230925

Year of fee payment: 6

Ref country code: FR

Payment date: 20230914

Year of fee payment: 6

Ref country code: DK

Payment date: 20230926

Year of fee payment: 6

Ref country code: BE

Payment date: 20230918

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20230919

Year of fee payment: 6

Ref country code: LV

Payment date: 20230918

Year of fee payment: 6

Ref country code: LT

Payment date: 20230918

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231106

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231011

Year of fee payment: 6

Ref country code: SI

Payment date: 20230918

Year of fee payment: 6

Ref country code: SE

Payment date: 20231010

Year of fee payment: 6

Ref country code: RO

Payment date: 20231002

Year of fee payment: 6

Ref country code: IT

Payment date: 20231012

Year of fee payment: 6

Ref country code: HU

Payment date: 20231004

Year of fee payment: 6

Ref country code: DE

Payment date: 20230915

Year of fee payment: 6

Ref country code: CH

Payment date: 20231101

Year of fee payment: 6

Ref country code: AT

Payment date: 20230925

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20230920

Year of fee payment: 6